BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer
Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the 'combined company'), which today acquired Streamex Exchange Corporation ('Streamex') as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain.
Key Highlights of the Appointment:
Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company.
Mr. Williams brings over 20 years of experience in capital markets, having held senior executive roles at OppenheimerFunds, and Wafra Inc.
At Wafra Inc., Mr. Williams grew assets under by more than 3-fold and consistently delivered asymmetric returns with top-quartile performance over all rolling five-year periods.
At OppenheimerFunds, Mr. Williams was the top-ranked equity analyst and led the firm's flagship fund.
Mr. Williams will help lead Streamex in its strategic positioning within the US$142.851 trillion global commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions.
As CIO, Mitch will lead the combined company's strategic vision and commodity tokenization initiatives, while overseeing key areas and reporting directly to Chief Executive Officer Henry McPhie.
Mitch commented, 'As an early investor in Streamex and later a Strategic Advisor I have been consistently impressed with Henry, Morgan, and the team and the innovative platform they've built. As a believer in disruptive technology, I see RWA tokenization as an incredibly scalable technology. For me it is a leap forward in finding real world applications for blockchain- a technology whose value has only begun to be realized. As an investor, I see Streamex as one of the few pathways for investors interested in both a hedge against fiat currency regimes and recurring revenue model.'
'We are thrilled to welcome Mitch as our new Chief Investment Officer,' said Henry McPhie, Chief Executive Officer of the combined company. 'Mitch's exceptional record of delivering disciplined, high-return investment strategies over his career at large New York funds paired with his collaborative leadership style perfectly complements our culture and growth ambitions. I am confident that his vision will unlock new opportunities for our shareholders, and I couldn't be happier to have him join our leadership team.'
About Mitch Williams
In his over two decades on Wall Street, Mitch has had a front row seat for disruptive technologies and market innovation. From his early role during Web 1.0 at Credit Suisse on the Internet Financial Services team to high-profile positions at OppenheimerFund and Wafra Inc managing multi-billion dollar domestic and global teams and portfolios, Mitch has driven consistent value creation for both his clients and employers.
At Wafra, Mitch grew assets under management by more than 3-fold during his tenure, delivering asymmetric returns characterized by upside capture consistently above 100% and downside capture below 100%. Under his lead Wafra achieved top-quartile performance for every rolling five-year period his team managed the Global Equity strategy. At OppenheimerFunds, he was a top-ranked analyst and took a leading role in managing one of the firm's flagship funds.
As Chief Investment Officer at Streamex, Mitch will apply his deep capital markets expertise and strategic vision to shape the firm's direction. Prior to this role, he served as a Strategic Advisor on Capital Markets to Streamex, working closely with Streamex founders Henry, Morgan, and Mathew August to develop and implement transformative business strategies.
Outside of his professional commitments, Mitch is an active mentor and speaker. He volunteers with the Michael Price Student Investment Fund at NYU's Stern School of Business and has spoken on investing at numerous leading universities. He holds an MBA from NYU Stern, where he was awarded the Stern Fellowship, and a BA from the University of Florida.
About Streamex Exchange Corporation
Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.
Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide.
Forward Looking statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the transaction will be obtained and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled 'Risk Factors' in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?
The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 to an estimated $381.5 billion by 2033. Two pharmaceutical giants, Eli Lilly (LLY) and Novo Nordisk (NVO), dominate this market. Both companies have created GLP-1 receptor agonists that have transformed obesity treatment: Eli Lilly's Mounjaro (tirzepatide) and Zepbound, and Novo Nordisk's Ozempic and Wegovy (semaglutide). Let's see which company is ahead of the game and has the best investment case right now. The Case for Eli Lilly Stock Valued at $684 billion, Eli Lilly has been a standout performer in the global pharmaceutical industry. Aside from its obesity treatments, it is well-known for developing groundbreaking treatments for autoimmune diseases, cancer, diabetes, Alzheimer's, and other conditions. LLY stock has fallen 6.4% year-to-date, compared to the S&P 500 Index's ($SPX) gain of 0.1%. Recently, Eli Lilly announced that Zepbound has demonstrated superior efficacy in weight loss compared to Novo Nordisk's Wegovy. The SURMOUNT-5 trial found that participants on Zepbound lost more body weight and waist circumference over 18 months than those on Wegovy. This superior efficacy is due to tirzepatide's dual action as a GLP-1 and GIP agonist, which boosts weight-loss effects. Financially, Eli Lilly reported a 45% increase in revenue in the first quarter of 2025, reaching $12.73 billion, thanks to strong sales from Mounjaro and Zepbound. Adjusted earnings increased 29% to $3.34 per share during the quarter. Mounjaro, in particular, saw a 113% year-over-year sales increase to $3.8 billion worldwide. Zepbound's sales increased threefold from the same quarter last year. Aside from the success of its weight-loss drugs, the company's non-incretin portfolio includes successful oncology, neuroscience, and immunology drugs, which are driving growth. The company anticipates 2025 revenue to be in the range of $58 billion to $61 billion, representing year-over-year growth of 28% to 35%. Eli Lilly has taken proactive measures to capitalize on the weight-loss drug boom. The company has handled supply chain issues more effectively than Novo Nordisk, resulting in improved product availability. Last year, the company launched Mounjaro in all major European markets and provided early stage access in China. In order to increase accessibility, the company has formed partnerships with telehealth providers and launched direct-to-consumer initiatives. Furthermore, Lilly's investment in orforglipron, an oral GLP-1 receptor agonist, has yielded encouraging results in Phase 3 studies. Patients lost significant weight, and the convenience of a pill form could transform obesity treatment, making it more accessible and appealing to a larger patient base. On Wall Street, Eli Lilly has earned an overall ' Strong Buy ' rating. Of the 25 analysts who cover the stock, 20 rate it a 'Strong Buy,' two a 'Moderate Buy,' and three recommend a 'Hold.' The average analyst price target of $991.46 suggests a 34.7% increase from current levels. Furthermore, the Street-high estimate of $1,190 implies that the stock could rally by up to 62% over the next year. The Case for Novo Nordisk Stock Valued at $311.7 billion, Novo Nordisk is a Denmark-based pharmaceutical company specializing primarily in diabetes care, obesity treatment, and other chronic disease therapies. Novo Nordisk's Ozempic and Wegovy have been instrumental in the company's growth. However, Eli Lilly's weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk's market dominance. Novo's stock has fallen nearly 20% year to date, compared to the overall market. In the first quarter of 2025, Novo Nordisk reported earnings per share of 6.53 DKK, in line with analyst expectations. Sales rose 18% year on year to 78.08 billion DKK, led by a 15% rise in Ozempic sales and an 83% increase in Wegovy sales. Despite these gains, the company faces significant challenges due to increased competition and shifting market dynamics. As a result, Novo Nordisk lowered its full-year guidance, projecting 2025 sales growth of 13% to 21%, significantly lower than Lilly's projections. Analysts who cover the stock expect Novo's revenue to grow by 25.5%, followed by earnings growth of 26%. While Eli Lilly's drugs have demonstrated superior efficacy, according to Leerink Partners analyst David Risinger, most people are unaware that Zepbound outperforms Wegovy. As a result, Novo continues to hold 65% of the market, while Lilly holds 34%. However, this may soon change. On Wall Street, Novo Nordisk stock has earned an overall ' Moderate Buy ' rating. Of the 18 analysts who cover the stock, eight rate it a 'Strong Buy,' seven say it is a 'Hold,' one says it is a 'Moderate Sell,' and two suggest a 'Strong Sell.' The average analyst price target of $101.93 suggests a 44% increase from current levels. Furthermore, the Street-high estimate of $160 implies that the stock could rally by up to 128% over the next year. The Verdict: Eli Lilly Takes the Lead Both Eli Lilly and Novo Nordisk continue to strengthen their incretin portfolios. However, based on clinical efficacy, market performance, strategic initiatives, and leadership stability, Eli Lilly currently has a competitive advantage over Novo Nordisk in the weight-loss drug market. Overall, Eli Lilly stock represents a better long-term investment.
Globe and Mail
2 hours ago
- Globe and Mail
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Hand Over Fist During the TACO Trade
As of closing bell on May 29, the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average have each generated roughly breakeven returns on the year. Normally, returns this mundane wouldn't be celebrated. But when you consider that each of the major stock market indexes declined by double digits just a month ago, getting back to even seems like a win. One of the more interesting aspects of the price movement in the stock market this year is annotating precisely when major volatility occurred. According to recently published data, it appears that the market's most pronounced declines and gains throughout 2025 can be traced back to major announcements from Washington, D.C. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Going a little deeper, whenever President Donald Trump has announced new tariff policies, the market reacted negatively. But when he has eased the pressure, stocks experienced sharp rebounds. This dynamic has become known as the TACO trade -- which stands for "Trump always chickens out." Considering the tariff situation is still very much ongoing, I suspect the capital markets will continue operating under heightened levels of uncertainty. Nevertheless, I see two no-brainer artificial intelligence (AI) stocks that look like great buys right now -- regardless of TACO trade volatility. After all, trading based on what you think Trump may or may not do next is a short-term and risky approach to investing, but focusing on solid long-term opportunities amid the chaos is a wise choice. Let's explore which stocks smart investors may want to consider buying the dip in as the TACO trade continues to make waves. 1. Nvidia The first AI stock on my list is semiconductor king Nvidia (NASDAQ: NVDA). Not only does Nvidia dominate the market for high-performance chipsets known as graphics processing units (GPUs), but the company's overall performance has essentially become the ultimate barometer by which the AI industry is measured. Said differently, if Nvidia's business is growing, investors tend to remain bullish on the AI boom. From a macro standpoint, Nvidia stands to benefit from ongoing investment in AI infrastructure. So long as cloud hyperscalers Amazon, Microsoft, and Alphabet, as well as tech titans like Meta Platforms, Oracle, and Apple, are building out data centers and buying chips, Nvidia is positioned to capture a portion of this multitrillion-dollar opportunity. As far as tariffs go, the biggest threat to Nvidia's business right now is its limited opportunity in China. New export controls coupled with rising competition from China-based Huawei has put Nvidia in a tough spot. Nevertheless, Nvidia has opportunities to maneuver around China-related headwinds. For instance, the company recently won multiple contracts in the United Arab Emirates (UAE) Kingdom of Saudi Arabia (KSA) -- each of which will be outfitting AI data centers with Nvidia's latest Blackwell GPUs. Moreover, rumors are swirling that Elon Musk's AI start-up, xAI, could be purchasing an estimated $40 billion worth of chips for its next GPU cluster. As I previously predicted, I think Nvidia stock is going to rebound considerably throughout the latter half of 2025 as I suspect tariff-driven fears will subside. NVDA Market Cap data by YCharts While there has been some recent valuation expansion following Nvidia's monster first-quarter earnings report, the stock still looks reasonable compared to historical levels on a forward price-to-earnings (P/E) basis. 2. Amazon Next up on my list is Amazon. On the surface, this might look like a head-scratcher. I'll concede that Amazon's core e-commerce business is pretty vulnerable to tariffs. However, I'm not distracted by these headwinds at the moment. Instead, I've been analyzing Amazon based on two other areas of the business. First, the company's cloud infrastructure unit, Amazon Web Services (AWS), continues to accelerate sales and widen operating margins. To me, this signals that the company's investments in AI have, so far, paid off. What's more lucrative, however, is that AWS accounts for the majority of operating profits for Amazon's entire business. This is important, because even during a time of economic uncertainty, the performance from AWS has remained strong and continued minting heaps of cash flow for Amazon. These robust unit economics provide Amazon with a high degree of operating leverage -- allowing the company to double down and reinvest in high-growth areas. In turn, Amazon has a unique ability to stitch more AI-driven investments across the broader fabric of its ecosystem -- from e-commerce, logistics, brick-and-mortar retail, advertising, streaming, subscription services, and even direct-to-consumer healthcare. It's these dynamics that may have caught the eye of billionaire hedge fund manager Bill Ackman, who recently joined Warren Buffett and Cathie Wood in adding Amazon to his portfolio. I think Amazon is well on its way to becoming Wall Street's first $5 trillion company. While the company could face some turbulence in the near term due to tariffs, this is not the first time the tech giant has dealt with a challenging regulatory environment. Yet, in the long run, Amazon has continued to manage to diversify its platform and build a number of multibillion-dollar businesses profitability. I see Amazon as an under-the-radar opportunity right now and I would take advantage of any dips as the TACO trade plays out. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Apple, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
From Search to Suggestion: How AI is Reshaping the Digital Ad Economy
What happens when the search bar disappears? That question isn't as far off as it sounds. Tools like ChatGPT, Perplexity, and Google's Gemini are already changing how people look for information online. Instead of typing keywords and clicking through results, users now ask questions and get direct answers, often with product recommendations or summaries built in. No ads, no links, and no search results page. For investors, this marks a major turning point. Digital advertising has long relied on keyword targeting and clicks. But as AI chat becomes more mainstream, that model is getting harder to rely on. Visibility now depends on whether your brand shows up in the answer at all. Companies that adapt early could gain an edge. Those who don't may be left behind. Cracks in the Search Engine Empire Online visibility used to follow a simple formula: buy some keywords, rank well in search results, and watch the traffic come in. Google and Baidu built their empires on this, while businesses poured money into SEO and SEM to stay competitive. But that model is starting to show its age. In Q1 2025, Alphabet Inc's (GOOG) core ad revenue grew by 8.5%, a slowdown from 10.6% in Q4 2024. Younger users are also skipping search altogether: nearly 40% of Gen Z now prefer TikTok or Instagram when searching for information online. Investors are already seeing the impact. Alphabet's P/E ratio has fallen from 25.57 in Q4 2024 to 19.52 as of May 2025. Baidu, Inc's (BIDU) revenue dropped 1% in 2024, ending the year at $18.24 billion. Search platforms may still dominate today, but staying relevant will mean evolving with how users discover content. The Rise of AI-Powered Discovery The way people find information is shifting fast. Instead of scrolling through search results, users are turning to AI tools like ChatGPT, Claude, and Gemini for direct answers. These systems don't just summarize, but they suggest products, services, and decisions in real time. Ask ChatGPT where to invest $500 or what the best CRM tool is, and it won't give you a list of links. It will offer a curated response based on how it processes data. Claude and Gemini do the same, bypassing traditional web rankings. That's a big change, and showing up on page one of Google isn't the only goal anymore. The real question is whether your brand appears in the AI's response. If your business depends on online visibility, it's worth understanding how to rank your website on ChatGPT, a new frontier in digital strategy. Staying discoverable in AI-generated results could soon be just as important as traditional SEO. For businesses and investors, this presents both a challenge and a window of opportunity. Ad-Tech Companies Getting Ahead of the AI Curve Some ad-tech companies aren't waiting, they're already shifting strategies to meet this moment. Why These Stocks Could Lead the Shift The Trade Desk (TTD) is moving early with Unified ID 2.0, a system built to replace third-party cookies while still allowing targeted ads. It's privacy-focused and designed for today's evolving data rules. As of late May 2025, the stock trades at a forward P/E of 43.48, far below its five-year average trailing P/E ratio of 232.63, suggesting a more reasonable valuation. Meta is using its in-house AI tools, including LLaMA 4, to sharpen ad targeting. It posted $42.31 billion in Q1 2025 revenue, beating analyst expectations. However, Reality Labs continues to weigh on results, with $17.7 billion in losses last year. Perion Network (PERI) is branching out into retail media and digital out-of-home ads, key after Microsoft changed its Bing deal, which affected Perion's search business. As of May 2025, its EV/EBITDA ratio is around 2.4, reflecting cautious investor sentiment for future growth. These companies are showing what adaptation looks like in real time. Who's At Risk? Some of the biggest names in tech still lean heavily on traditional ad models, and that could be a problem as user behavior starts to change. Alphabet continues to lead in digital advertising, pulling in $66.9 billio n in ad revenue in Q1 2025. But growth is slowing, and the company's model still depends largely on keyword-based ads, exactly the kind that become less useful when users start getting answers directly from AI. As people spend less time clicking through search results, Google's ad reach could face pressure. Baidu is in a similar spot in China. Its AI development is strong, but the business side hasn't caught up. In early 2025, overall revenue was up just 3%, and online ad sales actually dropped 6%. So far, Baidu hasn't figured out how to turn its AI tech into meaningful ad dollars. Amazon (AMZN) is a bit of a hybrid. Ad sales jumped 18% in Q1, driven by its retail platform. But while Amazon is growing fast in e-commerce advertising, it doesn't yet play a central role in AI-generated recommendations, which could become a bigger deal over time. As more users turn to AI tools for answers, these companies could see ad prices (like CPMs) dip unless they adapt their strategies for a post-search world. What Investors Should Watch Next The shift toward AI-powered discovery is still in its early stages, but the signs are already there and investors would be smart to keep an eye on them. Start with the basics: if cost-per-click (CPC) and cost-per-thousand impressions (CPM) start falling on traditional platforms like Google or Bing, it could be a red flag that attention is drifting elsewhere. Simultaneously, look for growth in AI-generated product placements where tools like ChatGPT or Gemini are surfacing brand suggestions inside their responses. Another key signal? Where the ad dollars are going. If more brands begin shifting their budgets toward 'in-AI' strategies, like optimizing for visibility inside generative answers instead of search rankings, it could mark the beginning of a much larger trend. The big picture here isn't just about better targeting or smarter data. The real prize is visibility, being the first answer a user sees when they ask a question. That's where the next digital advertising gold rush could happen. Don't Underestimate the Discovery Shift AI-powered discovery is already changing how people interact with the web. Instead of searching and clicking, users are now asking and receiving, fast, direct, and often without leaving the chat. For ad-tech companies, that's a big change, and one that creates both risk and opportunity. The players that adapt will find new ways to reach customers and unlock revenue. Those that don't may struggle to stay relevant. For investors, this isn't just about who's building the best AI models. It's about who shows up in the answer box. Because in this new landscape, the first response is the new front page of the internet.
